Skip to product details

Chemical product profile

HONGKUN / PRODUCT DIRECTORY

(R)-BoroLeu-(+)-pinanediol trifluoroacetate (1:1) | CAS 179324-87-9

A stereodefined, pinanediol-protected aminoboronate salt documented in bortezomib synthesis, requiring separate confirmation of the amino-bearing carbon configuration, the chiral diol fragment and the trifluoroacetate content basis.

CAS179324-87-9
Molecular formulaC17H29BF3NO4
Molecular weight379.2 g/mol

Product overview

This protected boroleucine fragment combines an (R)-aminoboronate, a (+)-pinanediol boronate ester and a 1:1 trifluoroacetate salt. The amino group provides the coupling site while boron remains protected. Qualification should address both stereochemical components, the intact ester and the salt-based calculation of usable content.

Chemical identity

Chemical name
(R)-BoroLeu-(+)-pinanediol trifluoroacetate (1:1)
CAS number
179324-87-9
Molecular formula
C17H29BF3NO4
Molecular weight
379.2 g/mol

Application context

In a reported bortezomib route, this protected aminoboronate salt is coupled with a pyrazinecarbonyl-L-phenylalanine fragment. It supplies the boroleucine portion while retaining pinanediol protection. Define the amino-carbon and diol stereochemistry, the 1:1 trifluoroacetate form and the assay calculation used for charging the coupling step.

Chemistry and synthetic role

The molecule is an α-aminoboronate: the amino-bearing carbon is also bonded to boron. The chiral pinanediol converts the boronic functionality into a protected ester, while trifluoroacetate defines the salt component. Carbon-centre configuration, diol configuration and salt stoichiometry are separate aspects of identity and require an explicit specification.

Quality review

Review both stereochemical components

Confirm the (R) amino-bearing carbon and the specified (+)-pinanediol configuration using identification and isomer-selective data. Review optical rotation as a complementary measurement.

Define the trifluoroacetate basis

Verify the intended 1:1 salt representation and whether assay is reported as salt, free-base equivalent or another defined basis. Agree treatment of water where relevant.

Confirm the protected boronate stage

Structure identification should distinguish the pinanediol ester from deprotected boronic acid material and other forms used elsewhere in the bortezomib sequence.

Preparing a specification

Specify CAS 179324-87-9, the complete stereochemical identity, (+)-pinanediol protection and 1:1 trifluoroacetate form. Agree chemical assay, stereoisomer controls and the salt-content calculation basis; add water or solvent criteria when needed for that calculation or the intended process.

Packaging and storage

Agree packaging, net weight and transport arrangements for the selected grade, quantity and destination. Confirm storage and handling conditions using the current SDS for the proposed material.

Documentation

Request the specification, batch COA and structural and stereochemical characterization appropriate to this protected salt. Confirm availability of the stereoisomer method, representative chromatograms and an explanation of trifluoroacetate and assay reporting. Obtain the actual supplier’s SDS.

Procurement questions

Is this free boroleucine or final bortezomib?

Neither. It is a pinanediol-protected aminoboronate defined by its trifluoroacetate salt identity.

Does one optical-rotation value establish all stereochemistry?

No. Both the amino-bearing carbon and the diol fragment matter; suitable identity and stereoisomer evidence should support qualification.

Why specify the salt basis in an RFQ?

A salt-based result and a free-base-equivalent result describe different reporting bases. Their meaning must be clear before comparing offers or calculating charges.

Technical sources
  1. PubChem CID 44244713 — structure propertiesPubChem / NCBI
  2. PubChem CID 44244713 — CAS and synonymsPubChem / NCBI
  3. (1R)-(S)-Pinanediol-1-amino-3-methylbutane-1-boronate, TrifluoroacetateSanta Cruz Biotechnology
  4. JP2010539183A — Bortezomib and process for its productionPatent applicant via Google Patents